Brooks Laboratories share news and announcements
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Last close ₹57.86down ₹3.23 (5.29%)BSE ₹58.02
Share price at the NSE close on 23 Oct 2026. Previous close ₹61.09.
52-week range of traded prices to 23 Oct 2026
₹36.30Low, 30 Mar 2026₹123.54High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 12.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 99,20064.6% delivered
Brooks Laboratories share news and announcements
454 announcements, routine notices left out, newest first. Page 2 of 10.
Mar 2025
4 Mar · Legal
Exchange has sought clarification from Brooks Laboratories Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
Feb 2025
Jan 2025
24 Jan · General Updates
7 Jan · General Updates
Dec 2024
18 Dec · Business
17 Dec · Board meeting
Nov 2024
9 Nov · Board meeting
5 Nov · Rating
Oct 2024
Sep 2024
19 Sep · Management
Aug 2024
14 Aug · Management
14 Aug · Board meeting
7 Aug · Management
7 Aug · Management
Jul 2024
23 Jul · Updates
May 2024
Apr 2024
Jan 2024
24 Jan · Board meeting
16 Jan · Board meeting
Dec 2023
27 Dec · Legal
The exchange asked on 27 Dec 2023
Nov 2023